Richard Gregory
Patrimonio netto: - $ in data 31/05/2026
Patrimonio netto: - $ in data 31/05/2026
Richard James Gregory is currently an Independent Non-Executive Director at CANbridge Pharmaceuticals Inc. since 2020.
Former positions include Independent Director at ProMIS Neurosciences, Inc. from 2016 to 2023; Chief Scientific Officer & Director at Canbridge Pharmaceuticals, Inc. (United States); Independent Director at Homology Medicines, Inc.; Chief Scientific Officer & Executive VP-Research at ImmunoGen, Inc. from 2015 to 2019; and Head-Research & Development at Genzyme Corp.
from 2011 to 2014.
Education includes a doctorate from the University of Massachusetts conferred in 1986 and an undergraduate degree from Virginia Polytechnic Institute & State University.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 12/01/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| CANBRIDGE PHARMACEUTICALS INC. | Direttore/Membro del Consiglio | 21/04/2020 |
| Società | Posizione | Fine |
|---|---|---|
| PROMIS NEUROSCIENCES, INC. | Direttore/Membro del Consiglio | 27/04/2023 |
| IMMUNOGEN, INC. | Direttore Tecnico/Scientifico/R&S | 30/08/2019 |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Direttore Tecnico/Scientifico/R&S | 01/01/2014 |
Canbridge Pharmaceuticals, Inc. (United States)
Canbridge Pharmaceuticals, Inc. (United States) BiotechnologyHealth Technology Operates as a biopharmaceutical company which research, development and commercialization of transformative therapies | Direttore Tecnico/Scientifico/R&S | - |
| Q32 BIO INC. | Direttore/Membro del Consiglio | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 8 |
|---|---|
ImmunoGen, Inc.
ImmunoGen, Inc. BiotechnologyHealth Technology Develops anticancer therapeutics | Health Technology |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. BiotechnologyHealth Technology Discovers and develops precision medicine solutions for the treatment of neurodegenerative & misfolded protein diseases | Health Technology |
University of Massachusetts
University of Massachusetts Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Virginia Polytechnic Institute & State University
Virginia Polytechnic Institute & State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Homology Medicines, Inc.
Homology Medicines, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage genetic medicines company | Health Technology |
Canbridge Pharmaceuticals, Inc. (United States)
Canbridge Pharmaceuticals, Inc. (United States) BiotechnologyHealth Technology Operates as a biopharmaceutical company which research, development and commercialization of transformative therapies | Health Technology |
CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale